Opportunity radar
4,186,134 patents indexed · 165,974,948 citations · issued 2005-01-04 → 2026-05-05
Showing50 of 77,862
Pharma (A61K)Therapy methods (A61P)Med devices (A61M)Agriculture (A01)Hand tools (B25)Consumer (A47)Energy (H01M)AI / ML (G06N)
| Patent # | Title | Assets | Issued | Expires | Fwd cites | Score |
|---|---|---|---|---|---|---|
| 12610975 | Family of heme binding proteins that increase chelated iron content and improve flavor of nutritional supplements and food products | 🖼🧊📄§ | 2026-04-28 | 2043-05-08 | 0 | 31 |
| 12610952 | Antimicrobial compositions and methods | 🖼🧊📄§ | 2026-04-28 | 2042-08-01 | 0 | 31 |
| 12612440 | Modified bovine G-CSF polypeptides and their uses | 🖼🧊📄§ | 2026-04-28 | 2042-12-22 | 0 | 31 |
| 12611399 | Movement disorders | 🖼🧊📄§ | 2026-04-28 | 2042-05-01 | 0 | 31 |
| 12611439 | Ionic self-assembling peptides | 🖼🧊📄§ | 2026-04-28 | 2043-02-09 | 0 | 31 |
| 12611409 | Combination therapy using a chemokine receptor 2 (CCR2) antagonist and a PD-1/PD-L1 inhibitor | 🖼🧊📄§ | 2026-04-28 | 2042-03-15 | 0 | 31 |
| 12611423 | Medical use of tafoxiparin | 🖼🧊📄§ | 2026-04-28 | 2043-05-02 | 0 | 31 |
| 12612463 | Mesothelin-targeted CD40 agonistic multispecific antibody constructs for the treatment of solid tumors | 🖼🧊📄§ | 2026-04-28 | 2044-01-19 | 0 | 31 |
| 12612462 | Treatment and inhibition of inflammatory lung diseases in patients having risk alleles in the genes encoding IL33 and IL1RL1 | 🖼🧊📄§ | 2026-04-28 | 2043-06-07 | 0 | 31 |
| 12612405 | Crystalline form of 1-(8-Bromopyrido[2,3-E][1,2,4]triazolo[4,3-a]pyrazin-4-Yl)-Nmethylazetidin-3-amine hydrogen sulfate monohydrate | 🖼🧊📄§ | 2026-04-28 | 2042-03-29 | 0 | 31 |
| 12611456 | Use of thiazole amide compounds for modulating human immune response | 🖼🧊📄§ | 2026-04-28 | 2040-09-16 | 0 | 31 |
| 12611459 | System and method for unbinding of plasma protein-bound active agents using an ultrasound system | 🖼🧊📄§ | 2026-04-28 | 2040-06-05 | 0 | 31 |
| 12611460 | Eyedrop compositions | 🖼🧊📄§ | 2026-04-28 | 2039-09-18 | 0 | 31 |
| 12611463 | Methods and immunogenic compositions relating to HER2 with selective sequence modifications | 🖼🧊📄§ | 2026-04-28 | 2043-12-04 | 0 | 31 |
| 12611464 | Modified clostridial neurotoxins as vaccine and conjugate vaccine platforms | 🖼🧊📄§ | 2026-04-28 | 2042-10-03 | 0 | 31 |
| 12611465 | Protein-enclosing polymeric micelle | 🖼🧊📄§ | 2026-04-28 | 2045-03-14 | 0 | 31 |
| 12611369 | Skin mimicry compositions and implants | 🖼🧊📄§ | 2026-04-28 | 2042-11-23 | 0 | 31 |
| 12611379 | Lipid nano drug delivery system targeting brain lesion and preparation method and application thereof | 🖼🧊📄§ | 2026-04-28 | 2040-11-13 | 0 | 31 |
| 12611380 | Solution and method for reducing the virulence of viruses, bacteria, yeasts, or fungus | 🖼🧊📄§ | 2026-04-28 | 2041-11-18 | 0 | 31 |
| 12611381 | Cationic hyaluronic acid coated spanlastics and preparation and application thereof | 🖼🧊📄§ | 2026-04-28 | 2040-04-02 | 0 | 31 |
| 12611382 | Method for manufacturing lipid particle | 🖼🧊📄§ | 2026-04-28 | 2042-09-09 | 0 | 31 |
| 12611496 | Peritoneal dialysate fluid generation system | 🖼🧊📄§ | 2026-04-28 | 2039-06-28 | 0 | 31 |
| 12611400 | Solid lipid nano-composition containing berberine and cinnamonaldehyde effective in treating diabetes, dyslipidemia, and method of preparing the same | 🖼🧊📄§ | 2026-04-28 | 2040-12-04 | 0 | 31 |
| 12611426 | Antibiotic composition comprising a composite of diatomaceous earth and zinc oxide, and combination preparation with the same | 🖼🧊📄§ | 2026-04-28 | 2042-07-07 | 0 | 31 |
| 12611428 | Processes for production of tumor infiltrating lymphocytes and uses of same in immunotherapy | 🖼🧊📄§ | 2026-04-28 | 2040-12-02 | 0 | 31 |
| 12612411 | Imidazopyrazine derivatives, process for preparation thereof, and their uses as luciferins | 🖼🧊📄§ | 2026-04-28 | 2045-06-23 | 0 | 31 |
| 12611640 | Continuous flow microfluidic system | 🖼🧊📄§ | 2026-04-28 | 2044-02-06 | 0 | 31 |
| 12611443 | Methods and compositions related to therapeutic peptides for cancer therapy | 🖼🧊📄§ | 2026-04-28 | 2041-06-14 | 0 | 31 |
| 12612375 | Antimicrobial and anticancer agents | 🖼🧊📄§ | 2026-04-28 | 2042-04-28 | 0 | 31 |
| 12612647 | Compositions useful in treatment of spinal muscular atrophy | 🖼🧊📄§ | 2026-04-28 | 2043-01-13 | 0 | 31 |
| 12605472 | Radiolabeling of anti-CD45 immunoglobulin and methods of use thereof | 🖼🧊📄§ | 2026-04-21 | 2040-09-17 | 0 | 31 |
| 12605471 | Cromolyn derivatives and related methods of imaging and treatment | 🖼🧊📄§ | 2026-04-21 | 2043-06-02 | 0 | 31 |
| 12605470 | Nanodroplet with layer-by-layer assembly | 🖼🧊📄§ | 2026-04-21 | 2040-11-20 | 0 | 31 |
| 12605473 | Methods for making radiolabeled anti-MET binding proteins | 🖼🧊📄§ | 2026-04-21 | 2043-12-29 | 0 | 31 |
| 12605465 | AAV-NAGLU vectors for treatment of mucopolysaccharidosis IIIB | 🖼🧊📄§ | 2026-04-21 | 2041-03-22 | 0 | 31 |
| 12605464 | Cyclohexane lipidoids for nucleic acid transfection and use thereof | 🖼🧊📄§ | 2026-04-21 | 2042-07-15 | 0 | 31 |
| 12605468 | Oxazine-based fluorophore compounds for nerve-specific imaging | 🖼🧊📄§ | 2026-04-21 | 2041-01-22 | 0 | 31 |
| 12605461 | Hydrogel compositions and uses thereof | 🖼🧊📄§ | 2026-04-21 | 2040-07-03 | 0 | 31 |
| 12605463 | Tolerogenic artificial antigen-presenting cells | 🖼🧊📄§ | 2026-04-21 | 2040-06-12 | 0 | 31 |
| 12605455 | CAR peptide for improved coronavirus survival | 🖼🧊📄§ | 2026-04-21 | 2041-03-19 | 0 | 31 |
| 12605451 | Targeted plasma protein degradation | 🖼🧊📄§ | 2026-04-21 | 2041-02-04 | 0 | 31 |
| 12605456 | Composition and method for HIP1-targeting inhibitor compounds | 🖼🧊📄§ | 2026-04-21 | 2042-05-28 | 0 | 31 |
| 12605436 | Chikungunya vaccine formulations | 🖼🧊📄§ | 2026-04-21 | 2040-08-10 | 0 | 31 |
| 12605442 | Production of vaccines comprising inactivated SARS-CoV-2 viral particles | 🖼🧊📄§ | 2026-04-21 | 2041-03-05 | 0 | 31 |
| 12605439 | Universal influenza vaccine compositions | 🖼🧊📄§ | 2026-04-21 | 2041-12-28 | 0 | 31 |
| 12605437 | Single shot Chikungunya virus vaccine | 🖼🧊📄§ | 2026-04-21 | 2040-08-10 | 0 | 31 |
| 12605429 | Proteins having pneumococcal capsule degrading activity and methods of use | 🖼🧊📄§ | 2026-04-21 | 2043-05-19 | 0 | 31 |
| 12605457 | Modified EGFR antibody with reduced affinity, drug conjugate, and use thereof | 🖼🧊📄§ | 2026-04-21 | 2041-11-19 | 0 | 31 |
| 12605433 | Antibody specifically binding to PTK7 and use thereof | 🖼🧊📄§ | 2026-04-21 | 2041-07-16 | 0 | 31 |
| 12605311 | Hydrogel structure | 🖼🧊📄§ | 2026-04-21 | 2041-02-05 | 0 | 31 |